A Biomarker-Based Scoring System to Assess the Presence of Obstructive Coronary Artery Disease in Patients With Myocardial Infarction

被引：0

作者：

Pascual, Maria Jesus Espinosa ^{[1
,2
]}

Carreno, Jose Antonio Carnicero ^{[3
]}

El Assar, Mariam ^{[3
]}

Rodriguez, Renee Olsen ^{[1
]}

Sanz, Alfonso Fraile ^{[1
,2
]}

Montes, Paula Rodriguez ^{[1
]}

Mancebo, Nuria Gil ^{[1
]}

Ferrer, Alberto Sanchez ^{[3
]}

Coronel, Barbara Izquierdo ^{[1
]}

Bello, Maria Alvarez ^{[1
]}

Munoz, Maria Martin ^{[1
]}

Hernandez, Veronica Camara ^{[4
]}

de Asua, Miguel de la Serna Real ^{[1
]}

Ybanez, Silvia Humanes ^{[1
]}

Callejas, Patricia Sosa ^{[3
]}

Munoz, Miguel Gutierrez ^{[1
]}

Caballero, Rebeca Mata ^{[1
,2
]}

Garcia, Paula Awamleh ^{[1
]}

Egido, Jesus angel Perea

Pais, Javier Lopez ^{[5
]}

Manas, Leocadio Rodriguez ^{[2
,3
]}

Martin, Joaquin Jesus Alonso ^{[1
,2
]}

机构：

[1] Hosp Univ Getafe, Cardiol Dept, Getafe, Spain

[2] Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Villaviciosa De Odon, Spain

[3] Hosp Univ Getafe, Fdn Invest Biomed, Aging & Frailty Dept, Getafe, Spain

[4] Hosp Univ Getafe, Dept Clin Anal, Getafe, Spain

[5] Hosp Clin Univ Santiago de Compostela, Cardiol Dept, La Coruna, Spain

来源：

CLINICAL CARDIOLOGY | 2025年 / 48卷 / 02期

关键词：

biomarkers; diagnosis; endothelial dysfunction; index; inflammation; MICAD; MINOCA; myocardial infarction; score;

D O I：

10.1002/clc.70090

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims: Approximately 10% of patients with myocardial infarction present with non-obstructive coronary arteries (MINOCA), whose characteristics differ from those with obstructive coronary lesions (MICAD). Inflammation plays a key role in myocardial infarction. This study aims to develop a biomarker-based index for accurate differentiation between MINOCA and MICAD. Methods: A prospective, observational cohort study including 111 patients admitted for myocardial infarction: 46 with MINOCA and 65 with MICAD. Blood samples were collected within the first 24 h to measure high-sensitivity C-reactive protein, interleukin-6, asymmetric dimethylarginine, and peak high-sensitivity troponin T. The association of these biomarkers with MICAD risk was analyzed using logistic regression. Scoring systems were developed using optimization algorithms to predict the diagnosis before coronary angiography, applied to both individual biomarkers and a combined index. Results: Patients had a mean age of 67 years (SD 13.3), with a male predominance (68.5%). Higher levels of IL-6 and high-sensitivity troponin T were significantly associated with increased MICAD risk (OR: 1.58; 95% CI: 1.01-2.46, and OR: 2.27; 95% CI: 1.61-3.26, respectively). As score increases, interleukin-6 and high-sensitivity troponin T increase the likelihood of MICAD classification, while higher asymmetric dimethylarginine levels reduce it. Each one-point increase in the combined index multiplies MICAD risk by six (OR:6.16, 95%CI: 2.72-13.95; p < 0.001). While individual indexes improved the diagnostic performance of biomarkers, the combined index demonstrated superior accuracy (AUC: 0.918). Conclusions: A biomarker-based scoring system was developed, achieving superior discriminatory capacity for differentiating MINOCA from MICAD compared to the individual analysis of biomarkers in absolute values or independent indexes.

引用

页数：8

共 24 条

[1]

Pasupathy S., Air T., Dreyer R.P., Tavella R., Beltrame J.F., Systematic Review of Patients Presenting With Suspected Myocardial Infarction and Nonobstructive Coronary Arteries, Circulation, 131, pp. 861-870, (2015)

[2]

Lopez-Pais J., Izquierdo Coronel B., Galan Gil D., Et al., Clinical Characteristics and Prognosis of Myocardial Infarction With Non-Obstructive Coronary Arteries: A Prospective Single-Center Study, Cardiology Journal, 29, pp. 798-806, (2022)

[3]

Byrne R.A., Rossello X., Coughlan J.J., Et al., ESC Guidelines for the Management of Acute Coronary Syndromes, European Heart Journal, 2023, 44, pp. 3720-3826, (2023)

[4]

Matter M.A., Paneni F., Libby P., Et al., Inflammation in Acute Myocardial Infarction: The Good, the Bad and the Ugly, European Heart Journal, 45, 2, pp. 89-103, (2024)

[5]

Liuzzo G., Ridker P.M., Universal Screening for hsCRP in Patients With Atherosclerotic Disease: A Major Therapeutic Opportunity, European Heart Journal, 45, 44, pp. 4731-4733, (2024)

[6]

Ridker P.M., Everett B.M., Thuren T., Et al., Antiinflammatory Therapy With Canakinumab for Atherosclerotic Disease, New England Journal of Medicine, 377, pp. 1119-1131, (2017)

[7]

Ridker P.M., Rane M., Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease, Circulation Research, 128, 11, pp. 1728-1746, (2021)

[8]

Abbate A., Van Tassell B., Bogin V., Et al., Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study, Journal of Cardiovascular Pharmacology, 84, 6, pp. 565-577, (2024)

[9]

Mazhar F., Faucon A.L., Fu E.L., Et al., Systemic Inflammation and Health Outcomes in Patients Receiving Treatment for Atherosclerotic Cardiovascular Disease, European Heart Journal, 45, 44, pp. 4719-4730, (2024)

[10]

Li Z., Lin C., Cai X., Et al., Anti-Inflammatory Therapies Were Associated With Reduced Risk of Myocardial Infarction in Patients With Established Cardiovascular Disease or High Cardiovascular Risks: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Atherosclerosis, 379, (2023)

← 1 2 3 →